Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

Douglas B. Johnson, Keith T. Flaherty, Jeffrey S. Weber, Jeffrey R. Infante, Kevin B. Kim, Richard F. Kefford, Omid Hamid, Lynn Schuchter, Jonathan Cebon, William H. Sharfman, Robert R. McWilliams, Mario Sznol, Donald P. Lawrence, Geoffrey T. Gibney, Howard A. Burris, Gerald S. Falchook, Alain Algazi, Karl Lewis, Georgina V. Long, Kiran PatelNageatte Ibrahim, Peng Sun, Shonda Little, Elizabeth Cunningham, Jeffrey A. Sosman, Adil Daud, Rene Gonzalez

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAF<sup>V600</sup>-mutant melanoma experiencing progression with single-agent BRAF inhibitor'. Together they form a unique fingerprint.

Medicine & Life Sciences